MOTS-c

MOTS-c is a mitochondrial-derived peptide — a 16-amino-acid signaling molecule encoded not in the cell nucleus but in the 12S rRNA region of mitochondrial DNA. First described in 2015, it was reported to promote metabolic homeostasis and, in mice, to reduce diet-induced obesity and insulin resistance [1]. Because its blood levels rise with physical activity and its biology overlaps with the metabolic benefits of exercise, it is frequently marketed as an "exercise mimetic."

That marketing has run well ahead of the human evidence. MOTS-c has no FDA approval for any indication, and — verified directly against PubMed — no published human randomized controlled trial has ever tested MOTS-c as a weight-loss treatment. The compelling metabolic and exercise-capacity findings come from mouse and cell studies; the human studies that exist measure circulating MOTS-c as a biomarker of exercise or aging, not as an administered drug. For the full evidence review, see our separate deep-dive: /research/mots-c-weight-loss-evidence.

MOTS-c is translated from a short open reading frame within the mitochondrial 12S ribosomal RNA gene, distinguishing it from the vast majority of proteins encoded by nuclear DNA. Once produced, it can act locally in the mitochondria and also translocate to the cell nucleus under metabolic stress, where it is proposed to help regulate genes involved in metabolism and antioxidant defense [2].

In mouse studies, MOTS-c has been shown to help regulate adipose-tissue (fat) homeostasis and to protect against the metabolic dysfunction that follows ovariectomy [4], and a 2021 Nature Communications paper described it as an exercise-induced, mitochondrially encoded regulator of age-dependent physical decline and muscle homeostasis — again with the headline results demonstrated in mice [3]. This is legitimate, actively studied mitochondrial biology; it is not the same thing as a demonstrated human weight-loss mechanism.

The founding 2015 paper in Cell Metabolism reported that MOTS-c improves insulin sensitivity and protects mice against diet-induced obesity [1]. Follow-up mouse work extended this to adipose-tissue regulation [4], and the 2021 Nature Communications study linked MOTS-c to exercise capacity and muscle homeostasis, also in mice [3]. These are the studies most often cited to sell MOTS-c online.

The human literature is real but answers a different question. A 2021 study found that a single bout of endurance exercise raises circulating levels of mitochondrial-derived peptides, including MOTS-c, in people [5] — establishing it as an exercise-responsive biomarker, not testing whether administering it causes weight loss. A search of PubMed for a human randomized controlled trial of MOTS-c as a weight-loss therapy returns zero results as of this verification. Reviews of mitochondrial-derived peptides in aging describe MOTS-c as a promising research target whose levels decline with age, while noting the therapeutic case in humans remains unproven [6].

There is no established or clinically validated human dose. Because no human randomized trial has tested MOTS-c as a weight-loss or metabolic therapy, no dose has been shown to be safe or effective in people — figures circulated on vendor sites and forums are not backed by clinical evidence. We do not publish a dosing protocol for this reason; a genuine dosing guide would imply a validated regimen that does not exist.

MOTS-c is not FDA-approved for any human indication and is not listed in DailyMed. It is sold online almost exclusively as a "research use only, not for human consumption" research chemical — a disclaimer that lets vendors ship it while sidestepping drug-marketing rules. Because it is unregulated, no agency verifies the identity, purity, sterility, or actual dose of what is in the vial, and self-injecting an unverified compound carries real risk of contamination, infection, and unknown dosing, with no proven human efficacy to offset that risk.

The two clinics in our directory that list MOTS-c prescribe it through a licensed clinician rather than shipping it as an unregulated research-use vial — that clinical oversight is a genuine, material difference from the grey market. It does not change the underlying evidence picture: even under a doctor's supervision, no human trial has shown MOTS-c causes weight loss, so treat it as an unproven, off-label compounded peptide and discuss the lack of efficacy data with your prescriber before starting it.